From the TWiV Vault This Week in Virology

In his weekly clinical update, Dr. Griffin discusses the how the pandemic influenced the healthcare job market before he reviews most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus, including all circulating variants in the US, discusses the safety of the prefusion RSV vaccine, if high or moderate dose of the quadrivalent influenza vaccine is better for protection against hospitalization, summarizes the new WHO COVID guidelines, revisits how to prevent pathogen transmission in healthcare setting, the under use of COVID oral antiviral and what occurs in persistently SARS-CoV-2 infected cells in culture after antiviral treatment, continues to dispel the myth of viral rebound, how to pay for paxlovid, when to use steroids and the benefits of convalescent plasma, how inflammatory markers change correlate with death when in ICU and if cognitive slowing is part of long COVID-19.

In his weekly clinical update, Dr. Griffin reviews most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus, including all circulating variants in the US, before discussing viral transmission to adults in healthcare setting, the recently EUA approved protein based COBREVAX vaccine, reviews quarantine guidelines, the use of simnotrelivr for mild to moderate COVID-19, how viral RNA may persist in your cell culture dish following antiviral therapy, continues to dispel the myth of viral rebound, how to pay for Paxlovid, , when to use steroids and the benefits of convalescent plasma, how Paxlovid may prevent long COVID and how complement dysfunction may lead to thromboinflammation during long COVID.

In his weekly clinical update, Dr. Griffin reviews most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US before discussing vaccine effectiveness in children and adolescents, how the pandemic impacted the socioemotional development of infants and toddlers, continues to dispel the myth of viral rebound, how to pay for Paxlovid, reviews quarantine guidelines, when to use steroids and the benefits of convalescent plasma, examines the role of immune aberrations in long COVID and how vaccination may protect against developing long COVID.

In his weekly clinical update, Dr. Griffin reviews recent measles outbreaks, prequalification of nOPV2 by the WHO and most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US before discussing COVID-19 deaths linked to SNPs in C-reactive protein, spread of recent viral variants, how early vaccination reduced hospitalization of those infected with XBB.1.5, reviewed quarantine guidelines, how oral antivirals reduce hospitalizations, dissociation of antiviral treatment from infection rebound, and long COVID, deaths due to administration of hydroxychloroquine, muscle abnormalities and extreme fatigue in individuals with long COVID-19 and how the economics of where you live make long COVID-19 more severe.

In his weekly clinical update, Dr. Griffin highlights global circulation of Mpox virus, reviews the most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US, and discusses the clinical outcome of hospitalized children under 5 years infected with SARS-CoV-2, the perinatal and neonatal outcomes including adverse effects of SARS-CoV-2 infection and virus transmission in Italy between early 2020 and 2022, the guidelines to improve home ventilation, the safety and efficacy of the oral anti-viral molnupiravir and the use of convalescent plasma as a long term treatment as well as treatment specifically for the immune compromised, the ineffectiveness of antibiotics for treating COVID-19, the association of olfactory dysfunction and the administration of corticosteroids and the safety of the RSV vaccines licensed last year.